$1,318.00
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Non-pharmacological treatment
9 Pharmacological treatment
10 Surgery
11 EPIDEMIOLOGY
14 MARKETED DRUGS
18 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020)
27 Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 18, 2020)
28 UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020)
29 Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020)
31 Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
33 KEY UPCOMING EVENTS
34 KEY REGULATORY EVENTS
34 Virpax And MedPharm Advance Diclofenac Spray
35 PROBABILITY OF SUCCESS
36 LICENSING AND ASSET ACQUISITION DEALS
36 LG Chem Expands Into Gene Therapy Via ICM Agreement
36 Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis
37 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
42 Recent events
45 BIBLIOGRAPHY
45 Prescription information
47 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2019–28
18 Figure 2: Overview of pipeline drugs for osteoarthritis in the US
18 Figure 3: Pipeline drugs for osteoarthritis, by company
19 Figure 4: Pipeline drugs for osteoarthritis, by drug type
19 Figure 5: Pipeline drugs for osteoarthritis, by classification
27 Figure 6: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020): Phase II – ROCCELLA
29 Figure 7: UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020): Phase II – Moderate to Severe Knee OA
31 Figure 8: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020): Phase III – FACT OA1, Phase III – FACT OA2
32 Figure 9: Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020): Phase IIb – Dose-Ranging
33 Figure 10: Key upcoming events in osteoarthritis
35 Figure 11: Probability of success in the osteoarthritis and osteoarthritis pain pipeline
39 Figure 12: Clinical trials in osteoarthritis
39 Figure 13: Top 10 drugs for clinical trials in osteoarthritis
40 Figure 14: Top 10 companies for clinical trials in osteoarthritis
40 Figure 15: Trial locations in osteoarthritis
41 Figure 16: Osteoarthritis trials status
42 Figure 17: Osteoarthritis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of osteoarthritis (knee or hip), 2019–28
15 Table 2: Marketed drugs for osteoarthritis
20 Table 3: Pipeline drugs for osteoarthritis in the US
26 Table 4: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020)
27 Table 5: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 18, 2020)
28 Table 6: UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020)
30 Table 7: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020)
31 Table 8: Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
37 Table 9: Historical global sales, by drug ($m), 2015–19
38 Table 10: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!